Add to my selection

GENVOYA

Medicine - Posted on Nov 27 2018 - Updated on Jun 12 2019

Active substance (DCI)

cobicistat
elvitégravir
emtricitabine
ténofovir alafénamide

history (2)

7/25/18

GENVOYA (emtricitabine, cobicistat, elvitegravir and tenofovir alafenamide), antiviral combination

High clinical benefit but no clinical benefit demonstrated in the treatment strategy for HIV-1 in children aged 6 – 12. GENV...

CAV :
54321

icône flèche
3/2/16

GENVOYA (emtricitabine, cobicistat, elvitegravir and tenofovir alafenamide), antiviral combination

Second-line treatment in the management of HIV. GENVOYA has the Marketing Authorisation in the treatment of type 1 human imm...

CAV :
54321

icône flèche

Technical information

ATC code

J05AR18

Manufacturer

GILEAD SCIENCES

Presentation

GENVOYA 150 mg/150 mg/200 mg/10 mg, comprimé pelliculé (code CIS : 65453475) Comprimé pelliculé (B/30) - Code CIP : 3400930037737

All our publications

Health economics

Immunologic deficiency syndromes

Sexually transmitted diseases